Literature DB >> 18948591

Kinase requirements in human cells: I. Comparing kinase requirements across various cell types.

Dorre A Grueneberg1, Sebastien Degot, Joseph Pearlberg, Wenliang Li, Joan E Davies, Amy Baldwin, Wilson Endege, John Doench, Jacqueline Sawyer, Yanhui Hu, Frederick Boyce, Jun Xian, Karl Munger, Ed Harlow.   

Abstract

shRNA loss-of-function screens were used to identify kinases that were rate-limiting for promoting cell proliferation and survival. Here, we study the differences in kinase requirements among various human cells, including freshly prepared primary cells, isogenic cells, immortalized cells, and cancer cell lines. Closely related patterns of kinase requirements among the various cell types were observed in three cases: (i) in repeat experiments using the same cells, (ii) with multiple populations of freshly prepared primary epithelial cells isolated from the same tissue source, and (iii) between nearly isogenic cells that differ from each other by the expression of a single gene. Other commonly used cancer cell lines were distinct from one another, even when they were isolated from similar tumor types. Even primary cells of different lineages isolated from the same tissue source showed many differences. The differences in kinase requirements among cell lines observed in this study suggest that the control of proliferation and survival may be significantly different between cell lines and that simple comparisons from any one cell to another may be misleading. Although the regulation of cell proliferation and survival are heavily studied areas, we did not see a bias in these screens toward the identification of previously known and well studied kinases, suggesting that our knowledge of molecular events in these areas is still meager.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948591      PMCID: PMC2575444          DOI: 10.1073/pnas.0808019105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

Review 2.  Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling.

Authors:  David A Fruman
Journal:  Curr Opin Immunol       Date:  2004-06       Impact factor: 7.486

3.  Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells.

Authors:  Amy Baldwin; Wenliang Li; Miranda Grace; Joseph Pearlberg; Ed Harlow; Karl Münger; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

4.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

Authors:  Jayanta Debnath; Senthil K Muthuswamy; Joan S Brugge
Journal:  Methods       Date:  2003-07       Impact factor: 3.608

5.  Assessment of the Alamar Blue assay for cellular growth and viability in vitro.

Authors:  G R Nakayama; M C Caton; M P Nova; Z Parandoosh
Journal:  J Immunol Methods       Date:  1997-05-26       Impact factor: 2.303

6.  An approach to genomewide screens of expressed small interfering RNAs in mammalian cells.

Authors:  Lianxing Zheng; Jun Liu; Sergei Batalov; Demin Zhou; Anthony Orth; Sheng Ding; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

7.  Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.

Authors:  T D Kessis; R J Slebos; W G Nelson; M B Kastan; B S Plunkett; S M Han; A T Lorincz; L Hedrick; K R Cho
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

9.  A resource for large-scale RNA-interference-based screens in mammals.

Authors:  Patrick J Paddison; Jose M Silva; Douglas S Conklin; Mike Schlabach; Mamie Li; Shola Aruleba; Vivekanand Balija; Andy O'Shaughnessy; Lidia Gnoj; Kim Scobie; Kenneth Chang; Thomas Westbrook; Michele Cleary; Ravi Sachidanandam; W Richard McCombie; Stephen J Elledge; Gregory J Hannon
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

10.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway.

Authors:  Katrien Berns; E Marielle Hijmans; Jasper Mullenders; Thijn R Brummelkamp; Arno Velds; Mike Heimerikx; Ron M Kerkhoven; Mandy Madiredjo; Wouter Nijkamp; Britta Weigelt; Reuven Agami; Wei Ge; Guy Cavet; Peter S Linsley; Roderick L Beijersbergen; René Bernards
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

View more
  43 in total

1.  Expression and purification of Src-family kinases for solution NMR studies.

Authors:  Andrea Piserchio; David Cowburn; Ranajeet Ghose
Journal:  Methods Mol Biol       Date:  2012

2.  Pro-survival activity of the MAK-V protein kinase in PC12 cells.

Authors:  Igor V Korobko; Svetlana V Kalinichenko; Elena V Korobko; Natalia N Ninkina; Sergey L Kiselev; Vladimir L Buchman
Journal:  Cell Cycle       Date:  2010-10-15       Impact factor: 4.534

3.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Authors:  Amy Baldwin; Dorre A Grueneberg; Karin Hellner; Jacqueline Sawyer; Miranda Grace; Wenliang Li; Ed Harlow; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.

Authors:  Van T Hoang; Katherine Nyswaner; Pedro Torres-Ayuso; John Brognard
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

5.  A kinase shRNA screen links LATS2 and the pRB tumor suppressor.

Authors:  Katrin Tschöp; Andrew R Conery; Larisa Litovchick; James A Decaprio; Jeffrey Settleman; Ed Harlow; Nicholas Dyson
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

6.  Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells.

Authors:  Amy Baldwin; Wenliang Li; Miranda Grace; Joseph Pearlberg; Ed Harlow; Karl Münger; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

7.  Too many roads not taken.

Authors:  Aled M Edwards; Ruth Isserlin; Gary D Bader; Stephen V Frye; Timothy M Willson; Frank H Yu
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

8.  GRK3 is essential for metastatic cells and promotes prostate tumor progression.

Authors:  Wenliang Li; Nanping Ai; Suming Wang; Nandita Bhattacharya; Vladimir Vrbanac; Michael Collins; Sabina Signoretti; Yanhui Hu; Frederick M Boyce; Karsten Gravdal; Ole J Halvorsen; Hawa Nalwoga; Lars A Akslen; Ed Harlow; Randolph S Watnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

Review 9.  Navigating the network: signaling cross-talk in hematopoietic cells.

Authors:  Iain D C Fraser; Ronald N Germain
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

Review 10.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.